XLON
TCF
Market cap4mUSD
May 22, Last price
0.75GBP
Name
Evgen Pharma PLC
Chart & performance
P/E
—
P/S
8.09
EPS
—
Div yield, %
—
Shrs. gr., 5y
28.04%
Rev. gr., 5y
%
Revenues
396k
-10.41%
Net income
-3m
L-22.41%
CFO
-3m
L-25.64%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Evgen Pharma plc, a UK-based pharmaceutical company founded in 2014, operates at the clinical development stage, concentrating on the creation of sulforaphane-based medications. Its mission is to combat various cancers and inflammatory conditions. The firm utilizes its proprietary Sulforadex technology, which is engineered to stabilize sulforaphane, in its product development. SFX-01 stands as their principal drug candidate, currently in Phase II clinical trials for metastatic breast cancer and Phase Ib/IIa trials for glioblastoma. Furthermore, SFX-01 is being investigated in preclinical stages for haematological malignancies and analogous disorders. The company also offers out-licensing services for its innovative technology.
Key people
Stephen Joseph Franklin
Chief Executive Officer, Executive Director
Richard Moulson
Chief Financial Officer, Director · since 2017
John Bradshaw
Finance Director, Executive Director, Company Secretary · since 2014
Hamina J. Patel
Chief Medical Officer · since 2016
Barry Clare
Executive Chairman of the Board
Alan Barge
Non-Executive Director
Susan Clement-Davies
Non-Executive Director · since 2018
Sue Foden
Non-Executive Director · since 2014
Legal address
ALDERLEY PARK
CONGLETON ROAD
NETHER ALDERLEY, CHE SK10 4TG
GB
CONGLETON ROAD
NETHER ALDERLEY, CHE SK10 4TG
GB
Headquarters
1S43
ALDERLEY PARK
CONGLETON ROAD
NETHER ALDERLEY, CHE SK10 4TG
GB
ALDERLEY PARK
CONGLETON ROAD
NETHER ALDERLEY, CHE SK10 4TG
GB
Previous name
EVGEN PHARMA LIMITED
Previous name
EVGEN PHARMA PLC
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||